

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1.. (Currently Amended) Tumor cells comprising a combination of MHC I and MHC II genes, occurring in humans, which genes are expressed, wherein the combination of MHC I and MHC II genes is selected from the group consisting of:

Peo- ple	HLA-A	HLA-C	HLA-B	HLA- DR	HLA- DQ	HLA- DP	Fre- quen- cy
Cor- nish (Kel- ten)	A*- 0101	Cw*- 0701	B*- 0801	DR*- 0301	DQ*- 0201	DP*- 0101	8.4%
Ger- man	A*- 0101	Cw*- 0701	B*- 0801	DR*- 0301	DQ*- 0201	DP*- 0401	4.8%
Ger- man	A*- 0101	Cw*- 0701	B*- 0701	DR*- 1501	DQ*- 0101	DP*- 0401	2.5%
USA	A*- 1001	Cw*- 0701	B*- 0801	DR*- 0301	DQ*- 0201	DP*- 0401	4.3%
Can- adian	A*- 0101	Cw*- 0701	B*- 0801	DR*- 0301	DQ*- 0201	DP*- 0101	5.1%
Au- stra-	A*- 0101	Cw*- 0701	B*- 0801	DR*- 0301	DQ*- 0201	DP*- 0101	7.6%

lian							
Japa- nese	A*- 2401	CBL	B*- 5201	DR*- 1501	DQ*- 0101	DP*- 0901	8.2%
Japa- nese	A*- 3301	CBL	B*- 4401	DR*- 1302	DQ*- 0101	DP*- 0401	4.9%
Indi- an	A*- 2401	CBL	B*- 6101	DR*- 1501	DQ*- 0101	DP*- 0402	4.1%
Thais	A*- 0201	Cw*- 1101	B*- 4601	DR*- 0901	DQ*- 0301	DP*- 0401	4.5%
Tai- wan	A*- 2401	Cw*- 0701	B*- 3901	DR*- 1201	DQ*- 0701	DP*- 1301	10.4%
Inuit	A*- 2401	CBL	B*- 4801	DR*- 0401	DQ*- 0701	DP*- 0201	9.4%
Sin- ga- pore	A*- 0201	Cw*- 1101	B*- 4601	DR*- 0901	DQ*- 0301	DP*- 0401	7.2%
Maori	A*- 0201	Cw*- 0101	B*- 5501	DR*- 1201	DQ*- 0701	DP*- 0101	8.1%
Bush- man	A*- 3001	CW*- 0401	B*- 5801	DR*- 1301	DQ*- 0101	DP*- 0401	8.2%
North Am.- Ne- groid	A*- 3601	CW*- 0401	B*- 5301	DR*- 1101	DQ*- 0101	DP*- 0101	1.1%
Bas- que	A*- 2901	CBL	B*- 4401	DR*- 0701	DQ*- 0201	DP*- 0201	5.4%
Java- nese	ABL	CBL	B*- 6201	DR*- 1201	DQ*- 0701	DP*- 0401	8.2%
Mon- goli- an	A*- 3001	Cw*- 0601	B*- 1301	DR*- 0701	DQ*- 0201	DP*- 0201	4.0%
Ura- lic	A*- 1101	CW*- 0401	B*- 3501	DR*- 0301	DQ*- 0201	DP*- 0101	3.1%

Claim 2. (Currently Amended) The tumor cells according to claim 1, wherein one or several genes code for ~~are also expressed for~~ co-stimulatory molecules, and wherein the one or several genes are expressed.

Claim 3. (Currently Amended) The tumor cells according to claim 2, wherein the co-stimulatory molecules comprise B7 or ~~and~~ CD44.

Claim 4. (Currently Amended) The tumor cells according to claim ~~any of claims 1 to 3~~, wherein one or several genes code for ~~are also expressed for~~ cytokines, and wherein the one or several genes are expressed.

Claim 5. (Currently Amended) The tumor cells according to claim 4, wherein the cytokines are interleukins, GM-CSG, TNF- α . or ~~and~~ interferon- γ .

Claim 6. (Canceled)

Claim 7. (Currently Amended) The tumor cells according to claim 1 ~~any of claims 1 to 6~~, comprising the following combination of MHC I and MHC II genes: A*0101; Cw*0701:B*0801; DRB1*0301; DQA1*0201; DQB1*0201; DPA1*0201; DPB1*0201.

Claim 8. (Currently Amended) The tumor cells according to claim 1 ~~any~~

~~of claims 1 to 7~~, comprising the following combination of MHC I/II genes and genes for IFN- γ , CD44 and GM-CSF:

A*0101; Cw*0701; B*0801; DRB1*0301; DQA1*0201; DQB1*0201; DPA1*0201; DPB1*0201; IFN- γ ; CD44; GM-CSF.

Claim 9. (Previously Presented) A method for producing the tumor cells according to claim 1, comprising the steps of:

- (a) tissue typing of tumor cells,
- (b) transfection of the tumor cells with MHC I and/or MHC II genes so as to obtain a combination of these genes, occurring in humans, and
- (c) selection for tumor cells which express the MHC I and MHC II genes.

Claim 10. (Previously Presented) The method according to claim 9, wherein the tumor cells are further transfected with one or several genes coding for co-stimulatory molecules and/or cytokines and selected for the expression of these genes.

Claim 11. (Currently Amended) Tumor cell library, comprising the tumor cells according to ~~any of claims 1 to 8~~ claim 1.

Claim 12. (Currently Amended) Vaccines, comprising the tumor cells according to ~~any of claims 1 to 8 and~~ claim 1 conventional auxiliary agents.

Claim 13. (Currently Amended) Use of the tumor cells according to ~~any of claims 1 to 8~~ claim 1, of the tumor cell library according to claim 11 or of the vaccines according to claim 12 for the prophylaxis and/or treatment of tumoral diseases.